Published in Fundam Clin Pharmacol on September 25, 2014
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
Universal definition of myocardial infarction. Circulation (2007) 11.69
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet (2008) 6.41
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med (2012) 4.37
Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet (2010) 3.36
Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis (2006) 2.72
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood (2005) 1.95
Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology (2005) 1.81
Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis Rheum (2010) 1.75
Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells. Circ Res (2012) 1.68
2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol (2014) 1.59
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) (2009) 1.52
QT interval prolongation after oxytocin bolus during surgical induced abortion. Clin Pharmacol Ther (2004) 1.47
Droperidol and ondansetron-induced QT interval prolongation: a clinical drug interaction study. Anesthesiology (2008) 1.40
Plasticity of surface structures and β(2)-adrenergic receptor localization in failing ventricular cardiomyocytes during recovery from heart failure. Circ Heart Fail (2012) 1.23
Can we override clopidogrel resistance? Circulation (2009) 1.18
Influence of endogenous oestrogens on QT interval duration. Eur Heart J (2003) 1.14
Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol (2003) 1.14
Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. Stem Cells Transl Med (2013) 1.13
Comment on "Clinical trials update from the European Society of Cardiology meeting 2005: CIBIS-III, by JGF Cleland and others". Eur J Heart Fail (2006) 1.10
Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology (2006) 1.08
In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother (2012) 1.02
Droperidol and ondansetron in vitro electrophysiological drug interaction study. Fundam Clin Pharmacol (2009) 1.01
Acute coronary syndrome in human immunodeficiency virus-infected patients: characteristics and 1 year prognosis. Eur Heart J (2010) 0.99
Effects of testosterone on ventricular repolarization in hypogonadic men. Am J Cardiol (2009) 0.97
Relationship between HIV protease inhibitors and QTc interval duration in HIV-infected patients: a cross-sectional study. Br J Clin Pharmacol (2008) 0.97
Cyclic nucleotide compartmentalization: contributions of phosphodiesterases and ATP-binding cassette transporters. Annu Rev Pharmacol Toxicol (2012) 0.97
QT interval measurement: evaluation of automatic QTc measurement and new simple method to calculate and interpret corrected QT interval. Anesthesiology (2006) 0.95
Cardiovascular safety of salmeterol in COPD. Chest (2003) 0.94
Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther (2003) 0.90
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol (2007) 0.90
Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. Clin Pharmacol Ther (2002) 0.88
Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther (2003) 0.85
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83
Postoperative analgesia and recovery course after major colorectal surgery in elderly patients: a randomized comparison between intrathecal morphine and intravenous PCA morphine. Reg Anesth Pain Med (2006) 0.83
STIM1 and Orai in cardiac hypertrophy and vascular proliferative diseases. Front Biosci (Schol Ed) (2013) 0.82
Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers. Hypertension (2013) 0.81
Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine. Clin Pharmacol Ther (2002) 0.81
Pharmacogenetics of acenocoumarol pharmacodynamics. Clin Pharmacol Ther (2004) 0.80
The role of the critical event committee in a major cardiovascular outcome study. Blood Press (2002) 0.80
Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther (2002) 0.79
[Practice guidelines 2007 for the treatment of arterial hypertension]. G Ital Cardiol (Rome) (2007) 0.79
[Guidelines for cardiac pacing and cardiac resynchronization therapy]. Rev Port Cardiol (2008) 0.78
Polyethylene wear in knee arthroplasty: a new sonographic sign. J Ultrasound Med (2008) 0.78
Clustering of acute and subacute stent thrombosis related to the introduction of generic clopidogrel. J Cardiovasc Pharmacol Ther (2013) 0.77
Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction. Clin Pharmacol Ther (2004) 0.76
Assessment of the effect of a single oral dose of telithromycin on sotalol-induced qt interval prolongation in healthy women. Br J Clin Pharmacol (2005) 0.76
Development and validation of a rapid and simple LC-MS/MS method for quantification of vemurafenib in human plasma: application to a human pharmacokinetic study. Ther Drug Monit (2015) 0.76
Determination of Colistin and Colistimethate Levels in Human Plasma and Urine by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Ther Drug Monit (2016) 0.75
Myocardial delivery of stromal cell-derived factor 1 in patients with ischemic heart disease: safe and promising. Circ Res (2013) 0.75
Corrected QT interval in anti-SSA-positive adults with connective tissue disease: comment on the article by Lazzerini et al. Arthritis Rheum (2005) 0.75
[Guidelines in cardiac pacing and resynchronization therapy]. Kardiol Pol (2007) 0.75
Droperidol-induced proarrhythmia: the beginning of an answer? Anesthesiology (2007) 0.75
Pharmacogenetics of clopidogrel. Curr Pharm Des (2012) 0.75
Prolonged ventricular repolarization in hypertension: is it heart rate? Arch Intern Med (2006) 0.75
Amiodarone concentrations in plasma and fat tissue during chronic treatment and related toxicity. Br J Clin Pharmacol (2009) 0.75
[2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment andmanagement]. Kardiol Pol (2014) 0.75
[In Process Citation]. Therapie (2012) 0.75
Conflicts of interests in the area of healthcare products and technology. Current state of affairs and recommendations. Therapie (2012) 0.75
Renal and vascular effects of S21402, a dual inhibitor of angiotensin-converting enzyme and neutral endopeptidase, in healthy subjects with hypovolemia. Clin Pharmacol Ther (2002) 0.75
Therapeutic drug monitoring of clozapine in a hemodialysed smoking patient with schizophrenia. Ther Drug Monit (2009) 0.75
Human plasma quantification of droperidol and ondansetron used in preventing postoperative nausea and vomiting with a LC/ESI/MS/MS method. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.75
How can the quality of medical data in pharmacovigilance, pharmacoepidemiology and clinical studies be guaranteed? Therapie (2013) 0.75
Effect on mode of death of heart failure treatment started with bisoprolol followed by Enalapril, compared to the opposite order: results of the randomized CIBIS III trial. Cardiovasc Ther (2011) 0.75
Poor ex vivo induction of T-cell responses to idiotype or tumor cell lysate-pulsed autologous dendritic cells in advanced pre-treated multiple myeloma. Leuk Lymphoma (2006) 0.75